Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 10/13/21

Rabih Said, MD


Dr. Rabih Said earned his MD from Lebanese University, Beirut, Lebanon, in 2002. He is ECFMG certified. He finished his Internal Medicine Residency and Hematology/oncology fellowship training at Northwell Health Staten Island University hospital in New York, NY, in 2011. From 2011 to 2012, Dr. Said was at MD Anderson Cancer Center for a special fellowship training in the Investigational Cancer Therapeutics (ICT) department focusing on designing, writing, and conducting early drug development trials (phase 1 trials) for patients with advanced cancer. In 2012, Dr. Said joined the University of Texas Health Science Center as an assistant professor in the Medical Oncology Division and as visiting assistant professor at the ICT department at MD Anderson Cancer Center where he conducted several phase 1 trials as principal investigator and co-investigator. In 2016, Dr. Said moved to Lebanon and joined the prestigious St. George Hospital University Medical Center and the University of Balamand as an associate professor where he was appointed as hematology/oncology fellowship director. He was also a consultant on the Lebanese national medical oncology committee of the Lebanese Ministry of Public Health. Dr. Said is board certified in both hematology and medical oncology.

About the Branch Chief

Jeffrey A. Moscow, MD Jeffrey A. Moscow, MD, joined the Investigational Drug Branch (IDB) in 2014 after serving part time since 2012, and was appointed Branch Chief in 2018. He is a graduate of Harvard University and the Geisel School of Medicine at Dartmouth. Dr. Moscow completed his pediatric residency at the University of Texas Southwestern in Dallas and a fellowship in pediatric hematology-oncology in the Pediatric Oncology Branch, NCI. More…